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BACKGROUND: During metastasis, cancer cells migrate away from the primary tumour and invade the circulatory system and distal
tissues. The stimulatory effect of growth factors has been implicated in the migration process. Placental growth factor (PlGF),
expressed by 30–50% of primary breast cancers, stimulates measurable breast cancer cell motility in vitro within 3h. This implies that
PlGF activates intracellular signalling kinases and cytoskeletal remodelling necessary for cellular migration. The PlGF-mediated motility
is prevented by an Flt-1-antagonising peptide, BP-1, and anti-PlGF antibody. The purpose of this study was to determine the
intracellular effects of PlGF and the inhibiting peptide, BP-1.
METHODS: Anti-PlGF receptor (anti-Flt-1) antibody and inhibitors of intracellular kinases were used for analysis of PlGF-delivered
intracellular signals that result in motility. The effects of PlGF and BP-1 on kinase activation, intermediate filament (IF) protein stability,
and the actin cytoskeleton were determined by immunohistochemistry, cellular migration assays, and immunoblots.
RESULTS: Placental growth factor stimulated phosphorylation of extracellular-regulated kinase (ERK)1/2 (pERK) in breast cancer cell
lines that also increased motility. In the presence of PlGF, BP-1 decreased cellular motility, reversed ERK1/2 phosphorylation, and
decreased nuclear and peripheral pERK1/2. ERK1/2 kinases are associated with rearrangements of the actin and IF components of the
cellular cytoskeleton. The PlGF caused rearrangements of the actin cytoskeleton, which were blocked by BP-1. The PlGF also
stabilised cytokeratin 19 and vimentin expression in MDA-MB-231 human breast cancer cells in the absence of de novo transcription
and translation.
CONCLUSIONS: The PlGF activates ERK1/2 kinases, which are associated with cellular motility, in breast cancer cells. Several of these
activating events are blocked by BP-1, which may explain its anti-tumour activity.
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A growing body of clinical and experimental evidence implicates
placental growth factor (PlGF) in pathologies, such as abnormal
blood vessel formation and cancer progression (DePrimo et al, 2007;
Ho et al,2 0 0 7 ;F i s c h e ret al, 2007, 2008), including breast cancer
(Parr et al, 2005). The PlGF is a member of the vascular endothelial
growth factor (VEGF) family first isolated from the placenta, but
later found to be normally expressed during wound healing and
in the thyroid (Li et al,2 0 0 6 ;M a e set al,2 0 0 6 ;K a g a w aet al, 2009).
In cancer cells, PlGF mediates a number of cellular activities that
promote metastasis, including attraction of endothelial cells for
establishment of a blood supply, enhanced invasiveness, and cellular
movement (Taylor et al, 2003; Casalou et al, 2007; Taylor and
Goldenberg, 2007). In all 30–50% of human breast cancers express
constitutive PlGF and its expression can be induced de novo in other
PlGF-negative tumour cells that survive radioimmunotherapy
(Taylor et al, 2002; Taylor and Goldenberg, 2007).
Alteration of growth factor receptor type or frequency, such
as HER2/neu in breast cancer, is associated with poor prognosis
or metastasis. The three known PlGF receptors are the receptor
tyrosine kinase (RTK) Flt-1 (also designated as VEGFR1), and the
glycosylphosphatidylinositol-anchored co-receptors, neuropilin-1
and -2 (NRP-1, NRP-2). Flt-1 is ectopically expressed by breast
cancer tissue, blood vessels, and breast cancer cell lines, in contrast
to normal breast tissue, in which NRP-1 is present and Flt-1 is
absent or near background (Starzec et al, 2006; Taylor and
Goldenberg, 2007). Therefore, it is possible that Flt-1 transmits
PlGF signals, including those that lead to enhanced motility, in
breast cancer.
Cellular motility is essential in the metastatic process, which
requires cellular migration away from the primary tumour, invasion
of surrounding tissue, entrance into the circulation, and then
migration into a distant organ or tissue. It is not surprising then that
alterations in cytoskeletal components responsible for motility mark
the progression from a normal to neoplastic and then to a metastatic
phenotype (Brotherick et al, 1998). The cytoskeleton is composed of
three elements, actin microfilaments, microtubules, and intermediate
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sfilaments (IFs). Some pro-metastatic growth factors, such as
epidermal growth factor, cause actin microfilaments to disassemble
stress fibres, restructure focal adhesion complexes, and form actin-
containing lamellipodia and filopodia for migration (Ronnstrand
and Heldin, 2001; Harper et al, 2007). The PlGF, as it stimulates
cellular migration, may also be a pro-metastatic growth factor.
The IFs, which include cytokeratins (CKs) and vimentin, are
structural components that allow cells and tissue to endure stress,
but IFs also participate in other cellular functions (Helfand et al,
2004; Oriolo et al, 2007). These proteins vary according to cell type
and cellular differentiation stage in normal tissue, and are often
dysregulated in primary cancers and cancer cell lines. The specific
intracellular consequences of altered IF expression are uncertain, but
it has been shown that co-expression of certain CKs and vimentin
augments carcinoma cell motility (Domagala et al, 1990; Chu et al,
1996; Hendrix et al, 1997; Thomas et al, 1999), and this was
demonstrated more specifically in a recent report by Schoumacher
et al (2010). CK8, CK18, and CK19 are expressed by normal breast
tissue, but often CK19 predominates in the progression to malig-
nancy, and its expression with vimentin, a mesenchymal IF, which is
not normally expressed by epithelium, is indicative of poor outcome
(Brotherick et al, 1998). This may be due to its role in promoting
cellular mechanical stability, its participation in cellular movement,
and its recently established role in stabilising invadopodia of
metastasising cells (Eckes et al, 1998; Schoumacher et al, 2010).
The changes in cytoskeletal microfilament and IF necessary for
migration or metastasis of cancer cells can be mediated through
activation of a number of intracellular pathways (Tsuganezawa
et al, 2002). Common intracellular targets of activated RTKs
are the extracellular-regulated kinases (ERKs) and phosphotidyl-
inositiol-3-kinase (PI3K).
In a previous report, we investigated PlGF/Flt1 inhibition using
the PlGF/Flt-1-expressing MDA-MB-231 xenograft metastatic
model, and the PlGF receptor-inhibiting peptide, BP-1. Treatment
with BP-1 was sufficient to inhibit the formation of pulmonary
metastases in mice implanted with MDA-MB-231 (Taylor and
Goldenberg, 2007). Using tissue microarrays it was also observed
that 30–50% of primary breast cancers express PlGF, Flt-1, or
both, whereas normal breast tissue expressed neither. Expression
of Flt-1 was not confined to the blood vessels, but was also on
tumour cells, and on breast tumour cell lines. This suggested that
PlGF may not only serve as an angiogenic factor, which it is, but
may also directly affect tumour cells expressing Flt-1. Evidence for
the effect of PlGF on tumours is also offered by clinical data
documenting that PlGF expression by human tumours, including
breast cancers, is predictive of poor clinical outcome, which is
characterised by aggressive disease, post-treatment recurrence,
and metastases (Chen et al, 2004; Parr et al, 2005; Wei et al, 2005;
Ho et al, 2007; Escudero et al, 2010).
This paper documents the results of in vitro analyses to determine
how PlGF promotes cellular motility. To do this, the activation of
several kinases by PlGF was investigated. The other goal of this
study was to determine how the peptide, BP-1, which demonstrates
anti-motility activity in vitro and anti-metastatic activity in breast
cancer xenograft models, exerts its anti-tumour effects (Taylor and
Goldenberg, 2007). The focus is on early changes in cellular motility
occurring within 1–3h of exposure to PlGF. The aggressive breast
cancer cell line, MDA-MB-231, which expresses PlGF and Flt-1, was
used primarily because it measurably increases migration in the
presence of PlGF within 3h of exposure.
MATERIALS AND METHODS
Cell lines and treatments
Cell lines were from the American Type Culture Collection
(Manassas, VA, USA). Treatment of cells with BP-1 (1mM)a n dP l G F
(1nM) was previously reported (Taylor and Goldenberg, 2007). The
concentration of inhibitors was actinomycin D (ActD, de novo
transcription), 1 or 10mgml
 1 (migration assay), 1mgml
 1 (immuno-
blots); cycloheximide (CHX), 3mgml
 1 (de novo translation);
PD98059 (PD98) (MEK pathway), 50mM; LY294002, 2mM (PI3K
pathway) (all from Calbiochem, La Jolla, CA, USA), wortmannin
(non-specific PI3K inhibitor), 5nM (Sigma, St Louis, MO, USA).
Migration assay
Spontaneous migration (wound) assays were performed as
previously described (Ilic et al, 1995; Mitra et al, 2005;
Wong et al, 2005; Taylor and Goldenberg, 2007) using cells treated
with PlGF, BP-1, inhibitor, or with antibody (1mgml
 1). Cells
were treated with PlGF either simultaneously with, or 15min
before inhibitors, as indicated. At the indicated time points up to
3h, coverslips were stained, mounted, and examined micro-
scopically by two blinded researchers. Five to ten  100 fields per
slide were evaluated by counting cells separated from the wound
edges and that appeared to be migrating. In two instances, results
were normalised by a constant factor (e.g., two-fold) to diminish
inter-experimental variation. The results are reported as the
average number of cells migrating into the wound per  100
field±s.d. from 5 to 10 fields per coverslip; one to two coverslips
per treatment per experiment, from two to five experiments,
depending on the treatment.
Immunoblots
Immunoblot analysis was performed using standard methods (Chu
et al,1 9 9 6 ) .I na l l ,1 0 mg of protein per lane was loaded on gels; the
primary antibody concentration was 1–5mgml
 1 (Santa Cruz
Biotechnology, Inc., Santa Cruz ,C A ,U S A ,o rC e l lS i g n a l i n g
Technology, Inc). (Beverly, MA, USA, http://www.cellsignal.com);
biotinylated secondary antibody, 0.1–2mgml
 1 (Santa Cruz Biotech-
nology, Inc. or Sigma), along with a half-standard dilution of an
avidin–biotin–HRP complex (Vector Laboratories, Inc., Burlingame,
CA, USA). Blots were developed in Supersignal West Pico Chemilu-
minescent substrate (Pierce, Rockford, IL, USA) and exposed on
Kodak X-AR film (Sigma). Blots were then stripped (Immunopure IgG
Elution Buffer, Pierce), and re-probed for actin or another marker.
Immunoblot signal was quantified by scanning densitometry
(Un-Scan-It Automated Digitizing System Software, Silk Scientific
Corp., Orem, UT, USA), using the total pixel density. Relative
expression of each protein is presented as the densitometry units,
or calculated as the ratio of signal density to actin density, or
compared to untreated controls.
Immunofluorescence, immunohistochemistry, and
detection of actin filament disruption
Depolymerisation of the actin cytoskeleton was determined
according to the method described by several groups (Arthur
and Burridge, 2001; Hirshman et al, 2001, 2005; Barros and
Marshall, 2005). Cells on coverslips were treated as indicated, fixed
in 3.7% methanol-free formaldehyde (in PBS) for 15min, followed
by permeabilisation in 0.5% Triton X-100 (T-X-100) in PBS for
5min, and blocked in 1% BSA in 0.1% T-X-100/PBS for 15min.
Cells were then labelled with 1U FITC-labeled phalloidin
(1mgml
 1) (Sigma), or labelled with both FITC-phalloidin and
AlexaFluor594-DNase I (AF-DNase I) (Invitrogen, Carlsbad, CA,
USA) (10mgml
 1) in 1% BSA/PBS for 20min at room temperature
in the dark.
Labelling of both F-actin (FITC-phalloidin) and G-actin
(AF-DNase I) together corrects for differences in cell size or
number per image, and thus aids in the quantification of changes
in the polymerised actin fibres (Chan et al, 1998; Hirshman et al,
2001). Isoproterenol, which measurably depolymerised the actin
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scytoskeleton after 1min (2 and 20mM) (MDA-MB-231), was the
depolymerisation control. Multiple views containing 420 cells per
 400 microscopic field were captured at room temperature with
Microfire software (Olympus America, Center Valley, PA, USA)
with the exposure time, image-intensity gain, and enhancement
held constant throughout to minimise intra- and inter-experi-
mental variation. For each actin form, the number of pixels of a
given fluorescence intensity was determined using Photoshop
software (Adobe Systems, San Jose, CA, USA) at intensity values
for AF-DNase I, 108±11; FITC-phalloidin, 159±10; non-cellular
background, 7±4 (DNase I) or 15±4 (phalloidin) (Chan et al,
1998; Hirshman et al, 2001; Papadopoulou et al, 2007).
Separate samples were permeabilised, blocked, and stained
with antibodies (e.g., p-ERK1/2) at a concentration of 1mgml
 1.
Primary antibody binding was detected by HRP-, FITC-, or
PE-labeled secondary antibodies. The location of phosphorylated
ERK (pERK) was determined for nuclear staining by counting cells
with darkly stained nuclei in six to ten  400 microscope fields at the
wound edges vs total number of cells (average number of cells per
treatment: 406±11). Blue counterstained nuclei were considered
negative. Nuclei with intermediate staining were counted, did not
vary substantially between samples, and so are not included in the
analysis. Cells were considered positive for pERK in the periphery if
40% of the cellular border was moderately to heavily positive.
For both bright field and fluorescent detection, mounted
coverslips were examined at  100 and  400 with an Olympus
BH-2 microscope (Olympus  10 objective lens numerical
aperture (NA) 0.30 or  40 objective, NA 0.70), and captured
digitally with an Olympus U-PMTVC camera using Microfire
software (Olympus America).
Statistics
Values are expressed as the mean±s.d. or s.e.m. to summarise
results. One-way analysis of variance or Student’s t-test was used
to determine the P-values. Pp0.05 was considered significant.
RESULTS
Immediate migration response is independent of de novo
mRNA or protein synthesis
We reported previously that MDA-MB-231 human breast cancer
cells incubated with exogenous PlGF at a concentration of 1nM
attained significantly (analysis of variance) increased invasive
potential (transwell) and motility (wound). MDA-MB-231 showed
consistent and significantly increased motility of 1.5- to 2-fold
within 3h after ‘wounding’ the cell monolayer. On the other hand,
invasion was measurable at a later time point (20h) for
MDA-MB-231, and the two other model cell lines, MCF-7 and
MDA-MB-468. Similar to MDA-MB-231, MCF-7 responded to PlGF
with increased invasiveness in 24h, but MDA-MB-468 was
unresponsive at all time points (Taylor and Goldenberg, 2007).
As the purpose of this study was to document the immediate effect
of PlGF on kinase activation within 1–3h of exposure, sponta-
neous motility assays (wound) with MDA-MB-231 were used
because of the rapid and measurable kinetics of PlGF-stimulated
migration, and because this cell line is tumourigenic and metastatic
in mice. Similar to 30–60% of primary breast cancers, MDA-MB-
231 also expresses the PlGF receptor, Flt-1. In addition, it expresses
NRP-1, an alternative PlGF receptor that is expressed by normal
breast (Bachelder et al, 2002; Taylor and Goldenberg, 2007).
The rapid response of MDA-MB-231 to PlGF suggested indepen-
dence from de novo transcription or translation. This was tested by
simultaneous addition of ActD (10mgml
 1), or CHX (3mgml
 1)
and PlGF to MDA-MB-231 motility assays. Neither treatment
significantly inhibited PlGF-stimulated migration (1.3-fold ActD
and 1.4-fold CHX) when compared with treatment with ActD or
CHX alone (Table 1). These results suggest that because de novo
mRNA and protein synthesis has minimal effects on the PlGF-
mediated motility observed within 3h of stimulation, activated
intracellular kinases may mediate motility.
Intracellular signalling: pERK and the PI3K pathways
Cellular movement entails changes in the cytoskeleton, which can
be mediated through activation of a number of intracellular
pathways, several of which may co-operate (Tsuganezawa et al,
2002). Common targets of activated RTKs, which include the PlGF
receptor Flt-1, are the ERKs and PI3K.
Activation (phosphorylation) of the ERK1/2 kinases was
assessed by immunoblot, and it was found that PlGF mediates
a 2- to 12.7-fold increase in phosphorylated ERK1/2 (pERK) (acti-
vated) in MDA-MB-231 and MCF-7 (Figure 1A shows representa-
tive immunoblots). On the other hand, MDA-MB-468 displayed
decreased pERK after 1h (Figure 1A). The ERK1/2 kinases are
the sole substrates of mitogen-activated protein kinase kinase
(MAPKK or MEK); therefore, the MEK-specific inhibitor, PD98059
(PD98), was used to distinguish the contribution of the ERK1/2
from other ERK kinases, and the p38MAPKs, which are not
substrates of MEK. PD98 (50mM) treatment ablated ERK phos-
phorylation when used alone or in the presence of PlGF (not
shown, MDA-MB-231). PD98 also inhibited PlGF-stimulated
migration of MDA-MB-231, as shown in Table 1. These results
suggest a relationship between PlGF, increased motility, and the
activity of the MEK/ERK1/2 pathway.
The PlGF cell surface receptors, Flt-1, and the glycosyl-
phosphatidylinositol-linked co-receptor, NRP-1, are differentially
expressed in normal breast tissue vs breast cancer. Soluble Flt-1,
anti-PlGF antibody, and the Flt-1-antagonising peptide, BP-1,
inhibited PlGF-stimulated cellular movement (Taylor and
Goldenberg, 2007). These findings, taken together with the ablation
of cellular motility by ERK1/2 inhibition (PD98) shown in Table 1,
suggest that ERK1/2 and Flt-1 participate in PlGF-driven breast
cancer cell movement.
The specificity of ERK activation by PlGF was further demon-
strated when lysates from anti-PlGF or anti-Flt-1 antibody-treated
Table 1 PlGF-stimulated cellular motility is independent of de novo
mRNA and protein synthesis, and inhibition of MEK/ERK pathway prevents
PlGF-stimulated migration
Treatment
Average number of migrating
cells per  100 field±s.d.
Untreated 4.3±2.5
PlGF (1nM) 7.4±2.8*
PD98059 (50mM) 4.0±2.3
PD98059+PlGF 3.7±3.2
LY294002 (2mM) 7.5±3.3*
LY294002+PlGF 7.6±2.6*
Untreated 8.5±3.9
PlGF (1nM) 11.2±4.5*
Actinomycin D (10mgml
 1) 7.5±4.0
Actinomycin D+PlGF 9.5±4.1*
Cycloheximide (3mgml
 1) 7.1±4.8
Cycloheximide+PlGF 9.9±5.3*
Abbreviations: ERK¼extracellular-regulated kinase; MEK¼mitogen-activated pro-
tein kinase kinase; PlGF¼placental growth factor. Five to ten  100 fields on
duplicate coverslips were evaluated for migrating cells by two researchers. Results
were averaged and the s.d. was determined. The 3-h time point from two to five
separate experiments is shown. *Po0.02 compared with control (PlGF vs untreated;
actinomycin D+PlGF vs actinomycin D; cycloheximide+PlGF vs cycloheximide;
LY294002 or LY294002+PlGF vs untreated).
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scells were probed for pERK by western blot analysis. Addition
of either antibody inhibited ERK phosphorylation (Figure 1A),
a result that further demonstrates the specificity of the PlGF-Flt-1-
mediated phosphorylation of ERK.
Active ERK kinases translocate to the nucleus and to the
cytoskeleton. As determined by immunohistochemistry, intra-
nuclear pERK was abundant, even in untreated MDA-MB-231 cells,
with 72–80% of nuclei staining heavily. The PlGF treatment
consistently increased the percentage of positive nuclei to 85±2%
(406±11 cells per treatment evaluated). Treatment of cells with the
BP-1 peptide, combined with PlGF, significantly decreased
the frequency of positive nuclei to 62±5% (Po0.001)
(Figure 1B). The pERK was also found in a dotted pattern at the
cellular periphery (see Materials and Methods) and in the
perinuclear region. The frequency of cells staining for peripheral
pERK differed among treatment groups with PlGF almost doubling
that of untreated cells (23±4 vs 12±3%, respectively, Po0.001
PlGF vs untreated). Treatment with BP-1 prevented the PlGF-
mediated increase in peripheral pERK (7±3% for PlGFþBP-1
(Po0.001 vs PlGF-only)).
PlGF did not detectably direct another ERK kinase, ERK5, which
also enhances cellular motility through disruption of cellular
adhesion and disassembly of the actin cytoskeleton to the cellular
periphery (Barros and Marshall, 2005) (not shown).
The ERK and the PI3K pathways may co-operate or oppose
each other in particular cellular responses, including motility. To
investigate the participation of PI3K pathways in PlGF-mediated
motility, MDA-MB-231 cells were treated with inhibitors of the
PI3K pathway.
Unlike the results obtained for ERK, motility was not inhibited
by the non-specific PI3K inhibitor, wortmannin (5nM) (not
shown), or with the more specific PI3K inhibitor, LY294002
(2mM, MDA-MB-231) (Table 1). Phosphorylated Akt, a common
downstream substrate of PI3K, was not increased or decreased by
addition of PlGF (MCF-7, not shown). Therefore, this pathway was
not detectably activated by PlGF, and most likely is not involved in
PlGF-stimulated migration of breast cancer cells.
IF expression by breast cancer cell lines
As PlGF-stimulated cellular motility and ERK activation were
prevented by BP-1 and anti-Flt-1 antibody, it was concluded that
PlGF may exert its effect on the cytoskeleton at least partially
through pERK. ERK kinases interact with both the actin and
the IFs of the cytoskeleton, including vimentin. Changes in IF type
and quantity are associated with breast cancer aggressiveness
and invasion. Normal breast epithelium does not express the
mesenchymal IF protein, vimentin. Phosphorylated ERKs1/2 bind
vimentin, stabilising ERK in its phosphorylated form, which in
turn leads to rearrangement of the vimentin network (Perlson et al,
2006; Henson and Vincent, 2008).
To investigate the relationship of ERK1/2, PlGF, and IF
expression in cellular motility, the relative amounts of vimentin
and the CKs 8/18 and 19 were first assessed for three breast cancer
cell lines (MDA-MB-231, -468, and MCF-7). Results are shown
in Figure 2A. MDA-MB-231 expresses abundant vimentin, but it
was undetectable in MDA-MB-468 and MCF-7 even after long
exposures (Figure 2A). The immunoblots showed that MDA-
MB-231, MCF-7, and MDA-MB-468 breast cancer cells all express
CK19, but the latter two lines are also high expressers of CK8/18
(Figure 2A). The MCF-7 CK8/18 to actin ratio was slightly
increased over the CK19 ratio, but both were abundantly expressed
(3.9±0.6 vs 2.9±0.32). On the other hand, MDA-MB-231, an
aggressive cell line that forms metastases from subcutaneous
MDA-MB-231
MCF-7
pERK1/2
pERK1/2
Actin
Actin
MDA-MB-468
U
P30 min
P2 h
P24 h
44 kDa
42 kDa
42 kDa
U P P+B a-P a-F C / P P+B a-P a-F C
44 kDa
50 M
42 kDa
42 kDa
44 kDa
42 kDa
42 kDa
U P P+B a-P a-F C / P P+B a-P a-F C
2 h
PIGF
PIGF + BP-1
/ 30 min
Figure 1 Activation of the extracellular-regulated kinases (ERKs) by PlGF, and inhibition by BP-1 and antibody treatment. (A) Representative blots of cell
lines treated as shown. Placental growth factor (PlGF) (1nM) (P); BP-1 (1mM)( B); anti-PlGF (a-P), or anti-Flt-1 (a-F), or C (irrelevant antibody), 1mgml
 1.
MDA-MB-468: U, untreated; P30min, PlGF treatment at 30-min time point; P2h, PlGF treatment at 2-h time point; P24h, PlGF at 24-h time point. MDA-
MB-231 and MDA-MB-468 actin controls are from the same blot; MCF-7 actin is from a separate, identical blot. (B) BP-1 depletes nuclear phosphorylated
ERK (pERK) in PlGF-treated cells. Micrographs of immunohistochemical staining of pERK in MDA-MB-231 cells. Treatments are shown. Original magnification
 400, bar 50mm.
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sxenograft tumours, expressed six-fold greater CK19 than
CK8/18 (Figure 2A). MDA-MB-468, also tumourigenic but non-
metastasising, expressed high levels of the CKs but no vimentin.
Alterations in vimentin expression vs PlGF
To assess whether PlGF would alter vimentin expression, MDA-
MB-231 was stimulated with PlGF for 1–3h, and the relative
amount of vimentin was determined by immunoblot. Increased
vimentin expression of 1.9- to 4-fold compared with the untreated
control was detected at the 1-h time point (Figure 2B, Po0.02).
Addition of the peptide BP-1 to the PlGF-containing cultures
resulted in a reversal of the PlGF-stimulated increase at 3h (1.07 of
untreated control) (Figure 2B).
To investigate this early effect of PlGF on vimentin expression
mediated by de novo mRNA or protein synthesis, MDA-MB-231
cells were incubated with sub-toxic doses of ActD and CHX
(1 and 3mgml
 1, respectively) to inhibit mRNA and protein
synthesis, respectively. Lysates were assessed for vimentin at
30min, 1h, and 3h. In these experiments incubation of MDA-
MB-231 with ActD resulted in declining vimentin over 3h. The
CHX treatment, on the other hand, caused a 50% decrease in
vimentin at 1h, but after 1h the amount of vimentin stabilised and
did not decline significantly thereafter. As shown on the graph in
Figure 2C, it appears that both de novo mRNA transcription and
translation are involved in vimentin production, but in the absence
of translation, a mechanism for stabilisation of vimentin is
activated that prevents or slows its loss.
In further experiments investigating the influence of PlGF on
vimentin expression, MDA-MB-231 cells were pre-incubated with
PlGF for 15min before addition of ActD or CHX. This resulted in
persistence of vimentin, even in the presence of ActD or CHX
(Figure 2C). Thus, it is probable that PlGF activates mechanisms
that promote the stability of vimentin independently of mRNA or
protein synthesis.
PlGF mediates stability of specific IF CKs
Just as expression of mesenchymal vimentin is associated with
aggressive breast cancer, changes in the pattern of CK expression
are also considered indicative of breast cancer aggressiveness and
motility, and co-expression of CK19 and vimentin is indicative of
poor clinical outcome (Brotherick et al, 1998; Buhler and Schaller,
2005). The effect of PlGF on CK expression was assayed, and it was
found that PlGF did not influence the abundance of CK8/18 (not
shown). However, after incubation for 1h with PlGF, CK19
increased 1.5-fold over untreated controls (P¼0.05) (MDA-
MB-231, four experiments). Treatment with BP-1 measurably
attenuated CK19 expression in PlGF-treated samples by 2h
(average 0.58±0.32 of PlGF-only, two experiments), suggesting
that autocrine PlGF signalling, which was blocked by the peptide,
may have a role in the maintenance of CK19 expression. A control
peptide did not affect CK19 expression (not shown).
The antagonistic effect of BP-1 on CK19 expression could be due
to interruption of PlGF-Flt-1-mediated stabilisation of CK19
protein. To further investigate the influence of PlGF on the
stability of CK19, cells were treated with either ActD or CHX at the
sub-toxic doses described above. Cumulative results are shown in
Figure 3A and Figure 3B shows representative blots. In the
CHX-treated samples, CK19 diminished to 50% of initial levels by
30min, remained at that level at the 1-h time point, after which it
declined to very low levels by 3h (as shown in Figure 3A). The
ActD treatment also brought about a steady decrease in CK19
(Figure 3A). These results suggest that CK19 expression is
regulated, in part, by transcription and translation.
In separate experiments, MDA-MB-231 was pre-treated with
PlGF for 15min before adding ActD or CHX. Pre-treatment
prevented the decrease in CK19 seen with single-agent treatment,
such that the CK19 levels remained higher than the untreated
controls (Figure 3A). Thus, the effect of PlGF on CK19 seems to be
independent of de novo transcription or translation, and may be
related to the rate of degradation of CK19.
PlGF stimulates rearrangement of the actin cytoskeleton
The microscopic appearance of PlGF-treated breast cancer cells
stained for F-actin differed from untreated cells by the appearance
of increased actin-rich punctate structures on the edges of the cells
(not shown). This observation may be due to the re-organisation of
the actin cytoskeleton as the cell becomes motile, and which has
been documented for other growth factors and carcinomas, for
example, epidermal growth factor (Chan et al, 1998; Harper et al,
2007). The state of the actin cytoskeleton was quantified by
determination of the F-actin (filamentous, polymerised) to G-actin
(non-polymerised) ratio using phalloidin and DNase I, which stain
F-actin and G-actin, respectively, as described in Materials and
methods. The ratio of F-actin to G-actin decreased to less than half
of untreated controls, indicating actin cytoskeleton rearrangement
on PlGF treatment (Figure 4). In contrast to the effect of PlGF
alone, addition of the inhibitory peptide, BP-1, to PlGF-treated
cultures prevented lowering of the F-actin to G-actin ratio
associated with PlGF.
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sDISCUSSION
The purpose of this study was to analyse the early events triggered
by PlGF in the responsive breast cancer cell, and elucidate how the
peptide, BP-1, works in inhibiting cellular motility in vitro, and in
preventing metastasis formation in xenograft models of breast
cancer (Taylor and Goldenberg, 2007). To carry out this, the effect
of inhibitors on cellular motility, a pro-metastatic behaviour, was
analysed. The results show that PlGF-driven breast tumour cell
motility include the activation of ERK1/2 kinases, stabilisation of
IF proteins, and re-organisation of the actin cytoskeleton. The
PlGF specificity of these results was shown by their ablation with
anti-Flt-1 antibody or BP-1.
The ERKs are activated by a number of different factors,
including c-Src, the G-protein-linked kinase Raf, and MEK (Barros
and Marshall, 2005; Chen et al, 2006). Increased pERK stimulated
by PlGF was reversed by treatment with BP-1 or a MEK-specific
inhibitor. Ablation of MEK not only prevented pERK formation,
but it also prevented PlGF-stimulated cellular migration. Thus, as
the only known substrates of MEK are the ERK1/2 kinases, it can
be concluded that PlGF-stimulated motility depends on activation
of the ERKs by MEK. This does not eliminate other potential ERK
activators, and preliminary data (not shown) suggest that Raf
participates in PlGF effects as well.
While this study was in progress, another report investigated
PlGF-mediated migration of leukaemia cells (Casalou et al, 2007).
Our findings are in agreement with this report, in that we found no
evidence of Akt involvement in PlGF-mediated breast cancer cell
movement. However, unlike Casalou et al, little evidence of p38
MAPK involvement in PlGF-mediated breast cancer cell movement
was found because movement was abrogated by inhibition of MEK,
which does not activate p38 MAPK. Therefore, it is unlikely that
p38 MAPK contributes substantially to the movement of breast
cancer cells in the presence of PlGF. Another point of difference
was the finding that VEGF had little to no effect on breast cancer
cell migration (Taylor and Goldenberg, 2007). This contrasts
with the results obtained by Casalou et al for leukaemia cells.
These differences may be due to different effects of VEGF and PlGF
on cancers of epithelial origin, such as breast cancer, in contrast to
cancers of hematopoietic origin, where the function of VEGF and
PlGF may be redundant.
When activated, the ERK kinases localise to the nucleus or to
focal adhesions where they are associated with motility by
interaction with cytoskeletal substrates, including IF proteins, the
actin cytoskeleton, and myosin light chain kinase (Zheng and
Guan, 1994; Schlaepfer et al, 1998; Arthur and Burridge, 2001;
Pawlak and Helfman, 2002; Yin et al, 2005). This study presented
evidence that PlGF promoted translocation of pERK1/2 to the
cellular periphery, and so there it may function to increase
motility.
Although CK18 and CK19 are expressed by normal breast
epithelium, their expression is often dysregulated in breast cancers
(Ferrero et al, 1990; Boecker et al, 2002). Aggressive MDA-MB-231
displays a pattern of predominant CK19 with little or no CK18,
whereas this is not the case for MCF-7 or MDA-MB-468, which
both produce abundant CK18 (and CK19). Human breast cancers
expressing high levels of CK18 (without vimentin), similar to
MCF-7 or MDA-MB-468, are less likely to recur. In addition,
MDA-MB-231 transfected with CK18 obtains an epithelial pheno-
type, reduces aggressiveness in tumour growth, and loses vimentin
expression (Buhler and Schaller, 2005). On the basis of the results
of this study, in which CK19 and vimentin expression rose on
PlGF stimulation, it is possible that RTK activation, such as Flt-1,
stimulates co-expression of CK19 and vimentin.
Likewise, vimentin, a mesenchymal IF protein not expressed by
normal breast cells, is associated with poorer clinical outcomes
and resistance to apoptosis and drugs (Yuan et al, 1997;
Stathopoulou et al, 2002; Willipinski-Stapelfeldt et al, 2005), as
well as increased metastasis and invasion (Hartig et al, 1998;
Tolstonog et al, 2001; Singh et al, 2003; Hu et al, 2004;
Schoumacher et al, 2010). McInroy and Maatta (2007) showed
that the aggressiveness of MDA-MB-231 depends on vimentin
expression, because its ablation impaired migration and invasion.
Our data show that disrupting PlGF or Flt-1 signalling with anti-
body or BP-1 depressed vimentin, CK19 expression, and motility
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other breast cancers, PlGF, or other abnormally expressed growth
factors, may maintain the high CK19 and vimentin levels necessary
for motility and invasion. The results also suggest that PlGF does
this by stabilising the proteins independently of ongoing
transcription and translation, and that, because of their concurrent
increase, both factors are controlled by intersecting or common
pathways, some of which are regulated by PlGF.
Flt-1 has been considered a cell surface-bound receptor (Wang
et al, 2000; Liu et al, 2005); however, nuclear expression that
delivered intracrine signals promoting breast cancer cell survival
through VEGF was reported by Lee et al (2007). Our previous
report indicated that exogenous PlGF, rather than VEGF,
promoted cellular movement, and that soluble Flt-1 and anti-PlGF
antibody blocked migration. In this study, we show that exogenous
anti-Flt-1 attenuates PlGF-driven phosphorylation of ERK also.
Except for the non-significant increase in nuclear translocation of
pERK with PlGF treatment, there is no indication that the PlGF
interactions leading to activation of ERK reported herein occurred
in the nucleus. In almost all cases, ERKs are activated by factors
associated with the inner leaflet of the plasma membrane and
cell surface receptors. Therefore, it can be concluded that PlGF
stimulates motility by interaction with cell surface Flt-1, rather
than nuclear Flt-1. The intracrine and cell surface functions of
Flt-1, one conferring survival and the other motility through PlGF,
are not mutually exclusive, and both promote metastasis.
In summary, this study describes for the first time, the effect of
the growth factor, PlGF, on the activation of key kinases, which
participate in increased cellular motility, a behaviour associated
with metastasis rather than tumour growth and tumour cell
proliferation. In other human cancers, ectopically expressed
growth factors may also drive metastasis by mechanisms similar
to those shown here for PlGF. For the breast cancer cell lines
studied, the specificity of the kinase activation and increased
migration was verified with antibody against both PlGF and Flt-1.
The peptide, BP-1, abrogates PlGF-driven cellular motility and
several of the PlGF-mediated changes in intracellular signalling,
and this may, in part, explain its anti-tumour activity.
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